NAFLD Histology: a Critical Review and Comparison of Scoring Systems
- 10 Downloads
Purpose of Review
Despite the emergence of non-invasive tests, liver biopsy remains the gold standard for the diagnosis of non-alcoholic fatty liver disease (NAFLD). This review will provide an overview of the histology of adult NAFLD with a focus on current scoring systems, histologic features that predict clinical outcomes, and areas in need of improvement.
Studies during the last two decades have established the histologic features used to categorize NAFLD into non-alcoholic fatty liver (NAFL) and non-alcoholic steatohepatitis (NASH), described histologic scoring systems that measure disease activity and fibrosis, and correlated histologic features with fibrosis progression and liver-related outcomes. Hepatocellular ballooning degeneration with associated lobular inflammation is the key feature that distinguishes NAFL from NASH. Fibrosis remains the most important feature in predicting relevant clinical outcomes; however, fibrosis and ballooning degeneration are tightly linked. Despite these advances, deficiencies remain in the histologic evaluation of NAFLD.
While histologic scoring systems have been developed and used in both clinical trials and clinical practice, areas of uncertainty exist, and refinement of current histologic indices is needed. Standardized assessment of these features is essential in clinical trials.
KeywordsNon-alcoholic fatty liver Steatohepatitis Liver fibrosis Ballooning degeneration
Compliance with ethical standards
Conflict of Interest
Rish K. Pai has received consulting income from Genentech, Eli Lilly, and Robarts Clinical Trials.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 1.• Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67(1):328–57 AASLD society guidelines for the diagnosis and management of patients with NAFLD. PubMedCrossRefGoogle Scholar
- 2.• Siddiqui MS, Harrison SA, Abdelmalek MF, Anstee QM, Bedossa P, Castera L, et al. Case definitions for inclusion and analysis of endpoints in clinical trials for nonalcoholic steatohepatitis through the lens of regulatory science. Hepatology. 2018;67(5):2001–12 Provides definitions for different NAFLD phenotypes for clinical trials.PubMedPubMedCentralCrossRefGoogle Scholar
- 7.•• Singh S, Allen AM, Wang Z, Prokop LJ, Murad MH, Loomba R. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol. 2015;13(4):643–54 Essential systematic review and meta-analysis of studies evaluating paired liver biopsies. PubMedCrossRefGoogle Scholar
- 11.•• Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology. 1999;116(6):1413–9 One of the first studies to correlate histologic features with fibrosis progression. PubMedCrossRefGoogle Scholar
- 14.Ballestri S, Nascimbeni F, Romagnoli D, Lonardo A. The independent predictors of non-alcoholic steatohepatitis and its individual histological features: insulin resistance, serum uric acid, metabolic syndrome, alanine aminotransferase and serum total cholesterol are a clue to pathogenesis and candidate targets for treatment. Hepatol Res. 2016;46(11):1074–87.PubMedCrossRefGoogle Scholar
- 25.•• Dulai PS, Singh S, Patel J, Soni M, Prokop LJ, Younossi Z, et al. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis. Hepatology. 2017;65(5):1557–65 Essential systematic review and meta-analysis of studies evaluating risk of mortality by fibrosis stage in NAFLD. PubMedPubMedCentralCrossRefGoogle Scholar
- 26.•• Angulo P, Kleiner DE, Dam-Larsen S, Adams LA, Bjornsson ES, Charatcharoenwitthaya P, et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology. 2015;149(2):389–397.e10 This study comprehensive evaluates a large number of liver biopsies and correlates histologic features with clinical outcomes.PubMedPubMedCentralCrossRefGoogle Scholar
- 27.• Younossi ZM, Stepanova M, Rafiq N, Makhlouf H, Younoszai Z, Agrawal R, et al. Pathologic criteria for nonalcoholic steatohepatitis: interprotocol agreement and ability to predict liver-related mortality. Hepatology. 2011;53(6):1874–82 This study emphasizes the seminal importance of fibrosis in predicting liver-related mortality. PubMedCrossRefGoogle Scholar
- 28.• Brunt EM, Kleiner DE, Wilson LA, Sanyal AJ, Neuschwander-Tetri BA, NASH CRN. Improvements in histologic features and diagnosis associated with improvement in fibrosis in NASH: results from the NASH clinical research network treatment trials. Hepatology. 2019;70(2):522-531. This study correlates histologic features that are associated with regression of fibrosis. Google Scholar
- 29.Brunt EM, Kleiner DE, Wilson LA, Unalp A, Behling CE, Lavine JE, et al. Portal chronic inflammation in nonalcoholic fatty liver disease (NAFLD): a histologic marker of advanced NAFLD-clinicopathologic correlations from the nonalcoholic steatohepatitis clinical research network. Hepatology. 2009;49(3):809–20.PubMedPubMedCentralCrossRefGoogle Scholar
- 30.Vilar-Gomez E, Calzadilla-Bertot L, Wai-Sun Wong V, Castellanos M, Aller-de la Fuente R, Metwally M, et al. Fibrosis severity as a determinant of cause-specific mortality in patients with advanced nonalcoholic fatty liver disease: a multi-national cohort study. Gastroenterology. 2018;155(2):443–457.e17.PubMedCrossRefGoogle Scholar
- 32.•• Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41(6):1313–21 This study describes development of the NAS, which is the most commonly used index in clinical trials. PubMedCrossRefGoogle Scholar
- 39.Kleiner DE, Brunt EM, Belt P, Behling CE, Gill RM, Guy C, et al. Extending the ballooning score beyond 2: a proposal for a new balloon score. Hepatology. 2015;62(S1):288A.Google Scholar
- 41.• Guidance for Industry: https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM627376.pdf. 2018;12. This document from the FDA describes proposed guidance for industry on clinical trial endpoints in NASH.
- 42.• Cheung A, Neuschwander-Tetri BA, Kleiner DE, Schabel E, Rinella M, Harrison S, et al. Defining improvement in nonalcoholic steatohepatitis for treatment trial endpoints: recommendations from the Liver Forum. Hepatology. 2019;70(5):1841-1855 Recommendations from the Liver Forum on clinical trial endpoints. PubMedCrossRefPubMedCentralGoogle Scholar
- 43.• Rinella ME, Tacke F, Sanyal AJ, Anstee QM, participants of the AASLD/EASL Workshop. Report on the AASLD/EASL Joint Workshop on clinical trial endpoints in NAFLD. Hepatology. 2019;70(4):1424-1436. This paper describes the results of a joint workshop between AASLD and EASL on clinical trial endpoints in NAFLD. PubMedCrossRefPubMedCentralGoogle Scholar